PE20190470A1 - Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronica - Google Patents
Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronicaInfo
- Publication number
- PE20190470A1 PE20190470A1 PE2019000060A PE2019000060A PE20190470A1 PE 20190470 A1 PE20190470 A1 PE 20190470A1 PE 2019000060 A PE2019000060 A PE 2019000060A PE 2019000060 A PE2019000060 A PE 2019000060A PE 20190470 A1 PE20190470 A1 PE 20190470A1
- Authority
- PE
- Peru
- Prior art keywords
- ethoxy
- fatty acid
- analogs
- diabetes
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Abstract
La presente invencion proporciona un compuesto o una sal farmaceuticamente aceptable de la Formula: X1 I V X2 S L O V P I G L L Q I L X3 E Q E K Q E K E K Q Q A K T N A X4 I L A Q V-NH2 en donde el X1 indica que el residuo I es modificado ya sea por acetilacion o metilacion en el extremo N- terminal; en donde X2 es L o T; en donde X3 es L o I; en donde X4 es Q o E; y en donde un residuo K modificado ("K ") en la posicion 29 es modificado a traves de la conjugacion al grupo epsilonamino de la cadena lateral K con un grupo de la Formula -X5 - X6, en donde X5 se selecciona del grupo que consiste de uno a cuatro aminoacidos; una a cuatro porciones de ([2 - (2-Amino- 15 etoxi) - etoxi] - acetil); y combinaciones de uno a cuatro aminoacidos y una a cuatro porciones de ([2 - (2- Amino- etoxi) etoxi] - acetil); y XG es un acido graso de C14-C24. En algunas materializaciones, el grupo de la Formula -X5- X6 es ([2 - (2 - Amino- etoxi) - etoxi] - acetil) 2- (yE) 2- CO- (CH2)x- C02H donde x es 16 o 18.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362711P | 2016-07-15 | 2016-07-15 | |
| US201662431682P | 2016-12-08 | 2016-12-08 | |
| US201762491385P | 2017-04-28 | 2017-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190470A1 true PE20190470A1 (es) | 2019-04-04 |
Family
ID=59501524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000060A PE20190470A1 (es) | 2016-07-15 | 2017-07-13 | Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronica |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10894817B2 (es) |
| EP (1) | EP3484495B1 (es) |
| JP (1) | JP2019525919A (es) |
| KR (1) | KR20190017982A (es) |
| CN (1) | CN109475592B (es) |
| AU (1) | AU2017295708B2 (es) |
| BR (1) | BR112018076693A2 (es) |
| CA (1) | CA3030965C (es) |
| CL (1) | CL2019000043A1 (es) |
| CO (1) | CO2018014026A2 (es) |
| CR (1) | CR20190015A (es) |
| DO (1) | DOP2019000007A (es) |
| EC (1) | ECSP19003047A (es) |
| ES (1) | ES2901477T3 (es) |
| IL (1) | IL264025A (es) |
| JO (1) | JOP20170153A1 (es) |
| MA (1) | MA45673A (es) |
| MX (1) | MX2019000661A (es) |
| PE (1) | PE20190470A1 (es) |
| PH (1) | PH12019500074A1 (es) |
| SG (1) | SG11201811737SA (es) |
| SV (1) | SV2019005808A (es) |
| TW (1) | TW201811821A (es) |
| WO (1) | WO2018013803A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| SI3436461T1 (sl) | 2016-03-28 | 2024-03-29 | Incyte Corporation | Pirolotriazinske spojine kot tam-inhibitorji |
| RS62872B1 (sr) | 2017-09-27 | 2022-02-28 | Incyte Corp | Soli derivata pirrolotriazina korisne kao tam inhibitori |
| WO2019140023A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140030A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140021A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140025A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140024A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| CN117771250A (zh) | 2018-06-29 | 2024-03-29 | 因赛特公司 | Axl/mer抑制剂的制剂 |
| US20200027555A1 (en) * | 2018-07-17 | 2020-01-23 | Lewis Pharmaceutical Information, Inc. | Patient centric drug analysis platform |
| WO2022038179A1 (en) | 2020-08-19 | 2022-02-24 | Sanofi | Crf2 receptor agonists and their use in therapy |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023285347A1 (en) * | 2021-07-12 | 2023-01-19 | Novo Nordisk A/S | Novel fatty acid modified urocortin 2 derivatives and the uses thereof |
| EP4234574A1 (en) | 2022-02-23 | 2023-08-30 | Corteria Pharmaceuticals | Crf2 receptor agonists and their use in therapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995034651A2 (en) | 1994-06-14 | 1995-12-21 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
| EP0845035A2 (en) * | 1995-06-13 | 1998-06-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| US20040034882A1 (en) | 1999-07-15 | 2004-02-19 | Vale Wylie W. | Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| JP4873825B2 (ja) * | 2000-08-04 | 2012-02-08 | リサーチ ディベロップメント ファンデーション | ウロコルチン蛋白質及びその利用 |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| NZ524477A (en) | 2001-03-15 | 2004-11-26 | Res Dev Foundation | Urocortin-III and uses thereof |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| GR1004664B (en) | 2002-11-26 | 2004-09-02 | Bionature E A Ltd | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| WO2005103690A2 (en) | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) |
| US7869958B2 (en) | 2004-08-09 | 2011-01-11 | Research Development Foundation | Structure-based modulators of B1 G-protein coupled receptors |
| KR20070112155A (ko) | 2005-02-08 | 2007-11-22 | 리서치 디벨럽먼트 파운데이션 | 가용성 Ｇ-단백질 연결 수용체(ｓＧＰＣＲ)와 관련된조성물 및 방법 |
| US7815905B2 (en) | 2006-01-27 | 2010-10-19 | Research Development Foundation | Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors |
| EP2114437A2 (en) * | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| EP2522351B1 (en) | 2007-06-13 | 2017-09-06 | Research Development Foundation | Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| WO2010053990A2 (en) * | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
| WO2011025905A1 (en) | 2009-08-28 | 2011-03-03 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
| AU2010315131A1 (en) | 2009-11-04 | 2012-05-31 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US9314506B2 (en) | 2011-10-24 | 2016-04-19 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| US20160166651A1 (en) | 2014-04-03 | 2016-06-16 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure |
| TWI700291B (zh) * | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| WO2017220706A1 (en) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
-
2016
- 2016-07-15 JO JOP/2017/0153A patent/JOP20170153A1/ar unknown
-
2017
- 2017-06-30 TW TW106121914A patent/TW201811821A/zh unknown
- 2017-07-13 CR CR20190015A patent/CR20190015A/es unknown
- 2017-07-13 MX MX2019000661A patent/MX2019000661A/es unknown
- 2017-07-13 SG SG11201811737SA patent/SG11201811737SA/en unknown
- 2017-07-13 JP JP2019501685A patent/JP2019525919A/ja not_active Withdrawn
- 2017-07-13 EP EP17746231.4A patent/EP3484495B1/en active Active
- 2017-07-13 KR KR1020197001249A patent/KR20190017982A/ko not_active Application Discontinuation
- 2017-07-13 MA MA045673A patent/MA45673A/fr unknown
- 2017-07-13 US US15/648,542 patent/US10894817B2/en active Active
- 2017-07-13 ES ES17746231T patent/ES2901477T3/es active Active
- 2017-07-13 BR BR112018076693-3A patent/BR112018076693A2/pt not_active Application Discontinuation
- 2017-07-13 AU AU2017295708A patent/AU2017295708B2/en not_active Ceased
- 2017-07-13 WO PCT/US2017/041922 patent/WO2018013803A1/en unknown
- 2017-07-13 PE PE2019000060A patent/PE20190470A1/es unknown
- 2017-07-13 CA CA3030965A patent/CA3030965C/en active Active
- 2017-07-13 CN CN201780043923.7A patent/CN109475592B/zh active Active
-
2018
- 2018-12-21 CO CONC2018/0014026A patent/CO2018014026A2/es unknown
- 2018-12-30 IL IL264025A patent/IL264025A/en unknown
-
2019
- 2019-01-07 CL CL2019000043A patent/CL2019000043A1/es unknown
- 2019-01-10 DO DO2019000007A patent/DOP2019000007A/es unknown
- 2019-01-11 PH PH12019500074A patent/PH12019500074A1/en unknown
- 2019-01-11 SV SV2019005808A patent/SV2019005808A/es unknown
- 2019-01-15 EC ECSENADI20193047A patent/ECSP19003047A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018013803A1 (en) | 2018-01-18 |
| MX2019000661A (es) | 2019-05-15 |
| US20180016318A1 (en) | 2018-01-18 |
| CA3030965C (en) | 2022-04-26 |
| JP2019525919A (ja) | 2019-09-12 |
| CR20190015A (es) | 2019-02-27 |
| IL264025A (en) | 2019-01-31 |
| SG11201811737SA (en) | 2019-01-30 |
| CN109475592A (zh) | 2019-03-15 |
| SV2019005808A (es) | 2019-04-04 |
| KR20190017982A (ko) | 2019-02-20 |
| EP3484495A1 (en) | 2019-05-22 |
| CL2019000043A1 (es) | 2019-06-07 |
| MA45673A (fr) | 2021-05-26 |
| CN109475592B (zh) | 2022-08-09 |
| AU2017295708B2 (en) | 2019-05-09 |
| JOP20170153A1 (ar) | 2019-01-30 |
| US10894817B2 (en) | 2021-01-19 |
| AU2017295708A1 (en) | 2018-12-20 |
| TW201811821A (zh) | 2018-04-01 |
| ES2901477T3 (es) | 2022-03-22 |
| ECSP19003047A (es) | 2019-01-31 |
| PH12019500074A1 (en) | 2019-07-29 |
| CA3030965A1 (en) | 2018-01-18 |
| EP3484495B1 (en) | 2021-09-08 |
| DOP2019000007A (es) | 2019-04-15 |
| BR112018076693A2 (pt) | 2019-04-02 |
| CO2018014026A2 (es) | 2019-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190470A1 (es) | Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronica | |
| HRP20191614T1 (hr) | Spojevi koji su suagonisti gip i glp-1 | |
| EA025267B1 (ru) | Водная фармацевтическая композиция этанерцепта, стабилизированная глутаматом | |
| CU20200045A7 (es) | Derivados de indol-2-carboxamidas sustituidos con pirazolo-piperidina activos contra el virus de la hepatitis b (vhb) | |
| CR20130667A (es) | Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales | |
| AR085155A1 (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos | |
| DOP2014000121A (es) | Derivados de betulina | |
| BR112016029582A2 (pt) | derivados de exendina-4 como agonistas de receptor de glucagon seletivos | |
| NZ629204A (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
| EA201270225A1 (ru) | СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| ECSP099601A (es) | Inhibidores de proteasa de serina | |
| UY33665A (es) | Derivado peptídico | |
| GT201400012A (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| UA108778C2 (xx) | Протираковий злитий протеїн | |
| BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
| ECSP13012755A (es) | Composiciones farmacéuticas que contienen un inhibidor de dgat1 | |
| EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с | |
| CL2017003097A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad celiaca | |
| EA033437B1 (ru) | Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний | |
| AR099201A1 (es) | Composiciones de limpieza que contienen plata estable | |
| BR112015024609A2 (pt) | proteína tendo atividade de xilose isomerase e utilização da mesma | |
| IN2014DN09367A (es) |